Krensavage Asset Management LLC grew its holdings in shares of Elanco Animal Health (NASDAQ:ELAN) by 0.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 200,967 shares of the company’s stock after acquiring an additional 967 shares during the quarter. Elanco Animal Health comprises approximately 2.1% of Krensavage Asset Management LLC’s holdings, making the stock its 9th largest position. Krensavage Asset Management LLC owned approximately 0.05% of Elanco Animal Health worth $6,336,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Macquarie Group Ltd. acquired a new position in Elanco Animal Health during the 3rd quarter worth $3,489,000. Chartwell Investment Partners LLC acquired a new position in Elanco Animal Health during the 4th quarter worth $251,000. Franklin Resources Inc. acquired a new position in Elanco Animal Health during the 3rd quarter worth $60,016,000. Janus Henderson Group PLC acquired a new position in Elanco Animal Health during the 3rd quarter worth $68,975,000. Finally, LPL Financial LLC acquired a new position in Elanco Animal Health during the 3rd quarter worth $313,000.
A number of brokerages have issued reports on ELAN. UBS Group began coverage on Elanco Animal Health in a research report on Wednesday. They set a “sell” rating and a $28.00 price target for the company. Bank of America upgraded Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $30.95 price target for the company in a research report on Monday. Morgan Stanley assumed coverage on Elanco Animal Health in a report on Wednesday, March 13th. They issued an “equal weight” rating and a $34.00 price objective for the company. Zacks Investment Research lowered Elanco Animal Health from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, William Blair assumed coverage on Elanco Animal Health in a report on Monday, February 11th. They issued a “market perform” rating and a $29.71 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. Elanco Animal Health presently has a consensus rating of “Hold” and an average target price of $33.14.
Elanco Animal Health (NASDAQ:ELAN) last announced its quarterly earnings data on Wednesday, February 6th. The company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.03. The firm had revenue of $799.30 million during the quarter, compared to analyst estimates of $804.07 million. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.12 EPS.
In related news, Director R David Hoover bought 20,000 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were bought at an average cost of $31.43 per share, with a total value of $628,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Elanco Animal Health Profile
There is no company description available for Elanco Animal Health Inc
Further Reading: Cryptocurrencies
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NASDAQ:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.